Gene symbol | E2F1 | Synonyms | E2F-1, RBAP1, RBBP3, RBP3 | Type of gene | protein-coding | |
Chromosome | 20 | Map location | 20q11.22 | dbXrefs | Entrez:1869 MIM:189971 HGNC:HGNC:3113 Ensembl:ENSG00000101412 AllianceGenome:HGNC:3113 | |
Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
Description | E2F transcription factor 1 |
Gene symbol | SPAM1 | Synonyms | HEL-S-96n, HYA1, HYAL1, HYAL3, HYAL5, PH-20, PH20, SPAG15 | Type of gene | protein-coding | |
Chromosome | 7 | Map location | 7q31.32 | dbXrefs | Entrez:6677 MIM:600930 HGNC:HGNC:11217 Ensembl:ENSG00000106304 AllianceGenome:HGNC:11217 | |
Description | sperm adhesion molecule 1 |
GTO ID | GTC3984 |
Trial ID | NCT03284268 |
Disease | Retinoblastoma |
Altered gene | E2F1|PH20 |
Therapeutic/Target gene | Therapeutic gene |
Therapy | DNA oncolytic virus |
Treatment | VCN-01 |
Phase | Not Applicable |
Recruitment status | Completed |
Title | Phase I Study, Single Site, Open Label With Dose Escalation, for Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma |
Year | 2017 |
Country | Spain |
Company sponsor | Fundació Sant Joan de Déu |
Other ID(s) | FSJD-RTB-2015 |
Vector information | |||||||||||||
|
Cohort1: dose level 1 | |||||||
|
|||||||
Cohort2: dose level 2 | |||||||
|
|||||||
Cohort3: dose level 3 | |||||||
|